Home
Search
Search Results
Previously Searched
3114 results found
Expand All
Apply All
3114 results found

FTC Comment Letter: Business Practices of Pharmacy Benefit Managers and Their Impact on Independent Pharmacies and Consumers (5/5/2022)
Capital Formation Policy Issues, ECS Digital Resources  •  April 23, 2024
Comments in response to FTC Solicitation for Public Comments on the Business Practices of Pharmacy Benefit Managers and Their Impact on Independent Pharmacies and Consumers.
Read More

Statement for the Record: "A Roadmap for Growth: Reforms to Encourage Capital Formation and Investment Opportunities for All Americans" (4/23/2023)
Capital Formation Policy Issues, ECS Digital Resources  •  April 23, 2024
Statement for the Record to House Financial Services Committee, Subcommittee on Capital Markets.
Read More

Testimony: "The Impact of Consolidation and Monopoly Power on American Innovation" (12/15/2021)
Capital Formation Policy Issues, ECS Digital Resources  •  April 23, 2024
Testimony of BIO’s Chief Policy Officer before the Senate Subcommittee on Competition Policy, Antitrust, and Consumer Rights on consolidation and monopoly power.
Read More

BIO Letter of Support: Short Sale Transparency and Market Fairness Act (7/29/2021)
Capital Formation Policy Issues, Educational  •  April 23, 2024
BIO Support of H.R. 4618, to amend short sale reporting requirements.
Read More

BIO Issue Brief: Committee on Foreign Investment in the United States (CFIUS) (9/22/2022)
Capital Formation Policy Issues, Advocacy  •  April 23, 2024
An overview of CFIUS and how the Administration’s focus on protecting the U.S. Biotech Industry could cause unintentional harm by impeding foreign investment and collaborations.
Read More

BIO Letter to Senate Banking Cmte: Proposals to Foster Capital Formation and Economic Growth in the Bioeconomy (3/18/2021)
Capital Formation Policy Issues, ECS Digital Resources  •  April 23, 2024
BIO Letter to Senate Banking Committee in support of proposals to foster capital formation for biotechs.
Read More

The State of Innovation in Vaccines and Prophylactic Antibodies for Infectious Diseases
Industry Analysis, ECS Digital Resources  •  April 23, 2024
This report focuses on vaccine innovation and success at the clinical stage, as well as the innovation of prophylactic antibodies in clinical trials.
Read More

IRA’s Impact on the US Biopharma Ecosystem
Industry Analysis, ECS Digital Resources  •  April 23, 2024
New research released by Vital Transformation (VT) shows that the Inflation Reduction Act (IRA) will stifle the ability of companies to continue research and development across a broad range of therapeutic areas.
Read More

The State of Innovation in Antibacterial Therapeutics
Industry Analysis, ECS Digital Resources  •  April 23, 2024
This report investigates recent investment into antibacterial innovation and the current clinical pipeline that will help bridge the gaps in the antibacterial armamentarium.
Read More

Earth Day: Biotech vs. Plastic
Good Day BIO Newsletter  •  April 22, 2024
Today is Earth Day, highlighting the importance of addressing plastic pollution—and biotech has a few answers. Continuing on the environment theme, BIO’s Beth Ellikidis spoke to Agri-Pulse about how we can advance biotech innovation. (546 words, 2 minutes, 43 seconds)
Read More